| Members |
targetComponentId |
| Dothiepin hydrochloride 25mg/5mL conventional release oral elixir |
Dosulepin 5 mg/mL oral solution |
| Dothiepin hydrochloride 25mg/5mL s/f elixir |
Dosulepin 5 mg/mL oral solution |
| Dothiepin hydrochloride 75mg/5mL conventional release oral elixir |
Dosulepin 15 mg/mL oral solution |
| Dothiepin hydrochloride 75mg/5mL s/f elixir |
Dosulepin 15 mg/mL oral solution |
| Double - DT - vaccination (& [pre-school] ) |
Preschool administration of diphtheria and tetanus vaccine |
| Double - DT - vaccination |
Preschool administration of diphtheria and tetanus vaccine |
| Double contrast barium meal |
Fluoroscopy of upper gastrointestinal tract with barium and air contrast |
| Double contrast barium meal |
Fluoroscopy of upper gastrointestinal tract with barium and air contrast |
| Double contrast barium swallow |
Fluoroscopy of esophagus and stomach with barium and air contrast swallow |
| Double pedicle flap graft |
Reconstruction using bipedicled flap |
| Down's incontinence apparatus |
Incontinence appliance (physical object) |
| Down's screening blood test NOS |
Down's screening status |
| Down's screening blood test NOS |
Down's screening - blood test |
| Down's syndrome NOS |
Complete trisomy 21 syndrome |
| Down's syndrome NOS |
Complete trisomy 21 syndrome |
| Doxazosin mesylate 8mg tablet |
Doxazosin (as doxazosin mesilate) 8 mg oral tablet |
| Doxepin hydrochloride 10mg/mL oral solution |
Product containing precisely doxepin (as doxepin hydrochloride) 10 milligram/1 milliliter conventional release oral solution (clinical drug) |
| Doxepin metabolite |
Product containing doxepin (medicinal product) |
| Doxorubicin hydrochloride 10mg injection solution vial |
Doxorubicin hydrochloride 10 mg powder for solution for injection vial |
| Doxorubicin hydrochloride 20mg injection solution vial |
Product containing precisely doxorubicin hydrochloride 2 milligram/1 milliliter conventional release solution for injection (clinical drug) |
| Doxorubicin liposomal 20mg/10ml injection |
Product containing precisely doxorubicin hydrochloride 2 milligram/1 milliliter conventional release solution for injection (clinical drug) |
| Doxycycline 100mg dispersible tablet |
Doxycycline 100 mg orodispersible tablet |
| Doxycycline 40mg m/r capsule |
Product containing precisely doxycycline 40 milligram/1 each prolonged-release oral capsule (clinical drug) |
| Doxycycline 75mg orally disintegrating tablet |
Doxycycline anhydrous (as doxycycline) 75 mg orodispersible tablet |
| Doxycycline calcium 50mg/5mL syrup |
Product containing precisely doxycycline anhydrous (as doxycycline calcium) 10 milligram/1 milliliter conventional release oral suspension (clinical drug) |
| Doxycycline hyclate 10% subgingival delivery system |
Product containing only doxycycline in oromucosal dose form (medicinal product form) |
| Doxycycline hyclate 200mg injection (pdr for recon) |
Product containing only doxycycline in parenteral dose form (medicinal product form) |
| Doxycycline hyclate 200mg powder for injection solution vial |
Product containing only doxycycline in parenteral dose form (medicinal product form) |
| Doxycycline monohydrate 25mg/5mL suspension |
Doxycycline anhydrous (as doxycycline) 5 mg/mL oral suspension |
| Draftsman NOS |
Draughtsman |
| Drain insertion - action |
Insertion - action (qualifier value) |
| Drainage bleb, functional |
Functional filtering bleb (finding) |
| Drainage of boil of skin NEC |
Drainage of boil of skin |
| Drainage of cyst NEC |
Drainage procedure |
| Drainage of cyst of pancreas into jejunum NEC |
Pancreaticocystojejunostomy |
| Drainage of female perineal abscess |
Drainage of perineal abscess (procedure) |
| Drainage of male periurethral abscess |
Drainage of periurethral abscess (procedure) |
| Drainage of organ NOC |
Drainage procedure |
| Drainage of organ NOC NOS |
Drainage procedure |
| Draughtsman NOS |
Draughtsman |
| Drechslera longirostrata |
Exserohilum longirostratum |
| Dressing - action |
Application - action |
| Dried factor IX fraction heated 600iu powder and solvent for injection solution vial |
Product containing only coagulation factor IX in parenteral dose form (medicinal product form) |
| Dried factor IX fraction heated 600iu powder for conventional release solution for injection solution vial |
Product containing only coagulation factor IX in parenteral dose form (medicinal product form) |
| Drilling of organ NOC |
Drilling |
| Drimaren brilliant yellow |
Textile colours and finishes patch test substance |
| Driving examination NOS |
Driving-related medical examination (procedure) |
| Driving examination NOS |
Driving-related medical examination (procedure) |
| Drop attacks in middle-aged woman |
Drop attack |
| Dropping sensation- pelvic floor |
Sensation of pelvic floor heaviness (finding) |
| Dropping sensation- pelvic floor |
Sensation of pelvic floor heaviness (finding) |
| Drostanolone propionate allergy |
Allergy to drostanolone (finding) |
| Drotrecogin alfa (activated) 5mg powder for infusion solution vial |
Drotrecogin alfa 5 mg powder for solution for injection vial |
| Drotrecogin alfa 20mg powder for infusion solution vial |
Product containing precisely drotrecogin alfa 20 milligram/1 vial powder for conventional release solution for injection (clinical drug) |
| Drug |
Pharmaceutical / biologic product (product) |
| Drug abuse in remission |
Harmful pattern of substance use in remission |
| Drug addiction counseling |
Counseling for substance dependence (procedure) |
| Drug addiction notif NOS |
Drug addiction notification status |
| Drug addiction notif NOS |
Drug addiction notification |
| Drug aerosol, 0,01% |
Drug aerosol |
| Drug aerosol, 0,04% |
Drug aerosol |
| Drug aerosol, 0,5% |
Drug aerosol |
| Drug cream, 0,01% |
Cream |
| Drug cream, 0,02% |
Cream |
| Drug cream, 0,025% |
Cream |
| Drug cream, 0,05% |
Cream |
| Drug cream, 0,1% |
Cream |
| Drug cream, 0,25% |
Cream |
| Drug cream, 0,5% |
Cream |
| Drug cream, 1% |
Cream |
| Drug cream, 2,5% |
Cream |
| Drug dependence |
Substance dependence (disorder) |
| Drug dependence - unspecified whether during pregnancy or the puerperium |
Substance dependence during pregnancy, childbirth and/or puerperium (disorder) |
| Drug dependence NOS |
Substance dependence (disorder) |
| Drug dependence NOS |
Substance dependence (disorder) |
| Drug dependence during childbirth, puerperium (& pregnancy) |
Substance dependence during pregnancy, childbirth and/or puerperium (disorder) |
| Drug dependence during pregnancy, childbirth and the puerperium |
Substance dependence during pregnancy, childbirth and/or puerperium (disorder) |
| Drug dependence during pregnancy, childbirth or the puerperium NOS |
Substance dependence during pregnancy, childbirth and/or puerperium (disorder) |
| Drug dependence in childbirth |
Substance dependence in childbirth |
| Drug dependence in mother complicating pregnancy, childbirth AND/OR puerperium |
Substance dependence in mother complicating pregnancy, childbirth and/or puerperium (disorder) |
| Drug dependence in remission |
Substance dependence in remission |
| Drug dependence, continuous |
Substance dependence, continuous |
| Drug dependence, episodic |
Substance dependence, episodic (disorder) |
| Drug for supraventricular arrhythmia |
Antiarrhythmic agent (substance) |
| Drug for ventricular arrhythmia |
Antiarrhythmic agent (substance) |
| Drug gel, 0,05% |
Gel |
| Drug gel, 0,1% |
Gel |
| Drug gel, 0,25% |
Gel |
| Drug groups and agents primarily acting on skin adverse reaction |
Adverse reaction to drug |
| Drug groups primarily affecting autonomic nervous system adverse reaction |
Adverse reaction to drug |
| Drug groups primarily affecting cardiovascular system adverse reaction |
Adverse reaction to drug |
| Drug groups primarily affecting central nervous system adverse reaction |
Adverse reaction to drug |
| Drug groups primarily affecting gastrointestinal system adverse reaction |
Adverse reaction to drug |
| Drug groups primarily affecting musculoskeletal system adverse reaction |
Adverse reaction to drug |
| Drug groups primarily affecting respiratory system adverse reaction |
Adverse reaction to drug |
| Drug groups primarily affecting the autonomic nervous system |
Product containing autonomic agent (product) |
| Drug hypersensitivity (& [NOS]) |
Propensity to adverse reactions to drug |
| Drug hypersensitivity |
Propensity to adverse reactions to drug |
| Drug hypersensitivity NOS |
Propensity to adverse reactions to drug |
| Drug induced rash (& ingestion dermatitis) |
Dermatitis caused by substance taken via oral route (disorder) |
| Drug level in urine specimen above therapeutic range |
Urine substance level above reference range (finding) |
FHIR